ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,576.98
0.07%
US Tech 100
19,930.80
0.19%
Dow Jones
39,291.97
-0.13%
Brent Oil
84.365
-0.39%
Bitcoin
57,771.29
-0.43%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. BioCardia Inc (BCDA) Quote

BioCardia Inc

BioCardia Inc (BCDA)

NASDAQ
3.01
0.10
(3.44%)
Closed July 09 4:00PM
Delayed by 15 minutes
2.98
-0.03
(-1.00%)
After Hours: 7:59PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.98
Bid
2.89
Ask
3.20
Volume
68,903
2.9001 Day's Range 3.1999
2.62 52 Week Range 43.1685
Market Cap
5.297M
Previous Close
2.91
Open
2.99
Last Trade
9
@
3.029
Last Trade Time
Financial Volume
$ 207,204
VWAP
3.0072
Average Volume (3m)
237,430
Shares Outstanding
1,820,274
Dividend Yield
-
PE Ratio
-0.46
Earnings Per Share (EPS)
-6.36
Revenue
477k
Net Profit
-11.57M

About BioCardia Inc

BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus o... BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.biocardia.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
BioCardia Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BCDA. The last closing price for BioCardia was $2.91. Over the last year, BioCardia shares have traded in a share price range of $ 2.62 to $ 43.1685.

BioCardia currently has 1,820,274 shares outstanding. The market capitalization of BioCardia is $5.30 million. BioCardia has a price to earnings ratio (PE ratio) of -0.46.

BCDA Latest News

More News

Form 8-K - Current report

July 08 2024
Edgar (US Regulatory)

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction

MULHOUSE, France, and SUNNYVALE, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia...

July 08 2024
GlobeNewswire Inc.

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and...

June 07 2024
GlobeNewswire Inc.

BioCardia Announces Reverse Stock Split

SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

May 21 2024
GlobeNewswire Inc.

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

May 14 2024
GlobeNewswire Inc.

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

May 01 2024
GlobeNewswire Inc.

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

April 25 2024
GlobeNewswire Inc.

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

March 27 2024
GlobeNewswire Inc.

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

March 20 2024
GlobeNewswire Inc.

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Partnership targets heart failure, the leading cause of death and a condition with limited treatment optionsBioCardia’s biotherapeutic delivery system with established safety profile enables...

March 13 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.13.472222222222.883.382.8570122.94493896CS
4-0.43-12.60997067453.413.932.62672933.26530431CS
12-2.6105-46.6952866475.59056.152.622374304.36550181CS
26-6.8525-69.69234680919.832510.052.623053085.77533187CS
52-38.87-92.879330943841.8543.16852.6284126413.42093654CS
156-50.72-94.450651769153.759.42.6248854021.20053406CS
260-75.62-96.208651399578.61292.6251979945.27924604CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SNGXSoligenix Inc
$ 7.42
(271.00%)
134.15M
ZAPPZapp Electric Vehicles Group Ltd
$ 17.9001
(93.72%)
45.5M
PEGYPineapple Energy Inc
$ 2.30
(91.67%)
77.57M
ATNF180 Life Sciences Corporation
$ 2.9017
(79.12%)
31.21M
QUREuniQure NV
$ 6.65
(75.93%)
51.49M
NVOSNovo Integrated Sciences Inc
$ 0.4874
(-35.44%)
3.12M
FAASDigiAsia Corporation
$ 3.65
(-34.17%)
49.17k
INDVIndivior PLC
$ 10.18
(-33.64%)
2.95M
CLEUChina Liberal Education Holdings Ltd
$ 0.3905
(-31.59%)
9.24M
HUBCWHub Cyber Security Ltd
$ 0.0165
(-31.25%)
1.9k
NVDANVIDIA Corporation
$ 131.38
(2.48%)
287.03M
MAXNMaxeon Solar Technologies Ltd
$ 0.2451
(-9.22%)
233.65M
TSLATesla Inc
$ 262.33
(3.71%)
160.74M
SNGXSoligenix Inc
$ 7.42
(271.00%)
134.15M
INTCIntel Corporation
$ 34.59
(1.77%)
97.8M

BCDA Discussion

View Posts
JB40 JB40 1 week ago
Understand and agree. They get little to no traction on the market. Although, most important imo is they do get traction with the largest health insurer in the country putting millions into BCDA's trials. Bizarre to me that few are paying attention to such a large indication as I'm sure you are aware with them being in such a late stage of their trials. Small burn and only need a small amount of capital to get to the Phase 3 readout. They already have 90% of the Phase 3 BCDA01 data, so I guess we will see what happens with the final data set.
👍️0
murocman murocman 1 week ago
Yes. Have a personal interest as I have heart disease.

Have traded it sporadically.

Disappointed that don’t ever seem to get much traction with this therapy even with good data.

Murocman
👍️0
JB40 JB40 1 week ago
Been tracking this company for years. Anyone else?
👍️0
Monksdream Monksdream 2 weeks ago
BCDA new 52 week low
👍️0
Muhbruh Muhbruh 3 weeks ago
$BCDA catalysts;
''Our planned Morph-DNA submission to the FDA for approval of a product family from 5 French to 8 French diameters is on track for submission in the second quarter of 2024''
''Q2: Enrollment in the CardiAMP Cell Therapy Heart Failure Trial''
''Q2: Completion of low dose cohort''
''Q2: Third revenue sharing partnership agreement''
👍️0
Monksdream Monksdream 4 weeks ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 1 month ago
BCDA new 52 week low
👍️0
tw0122 tw0122 1 month ago
Watching news .. 08:17 AM EDT, 06/07/2024 (MT Newswires) -- BioCardia (BCDA) said Friday that the US Patent Office has granted a patent for the company's radial and transendocardial biotherapeutic delivery catheter through 2036.

The Helix biotherapeutic delivery system is being evaluated in ongoing clinical trials, according to BioCardia. It relates to medical procedures and systems for substance delivery to the heart through a radial artery and for the intracardiac delivery of cellular aggregates and other materials, the company said.

BioCardia's stock climbed more than 44% in recent Friday premarket activity.

Price: 6.3000, Change: +1.93, Percent Change: +44.16
👍️0
Termite7 Termite7 2 months ago
Keep watching.........
👍️0
TheGreenReaper TheGreenReaper 7 months ago
Let's get a rise back up
👍️0
Triple nickle Triple nickle 8 months ago
Easy money
👍️0
Triple nickle Triple nickle 8 months ago
Grabbed 1.20
👍️0
Triple nickle Triple nickle 8 months ago
Got 1.28’s now to push it
👍️0
Triple nickle Triple nickle 8 months ago
Tapping it up
👍️0
subslover subslover 8 months ago
Already past Pluto now heading for the next solar system
👍️0
Triple nickle Triple nickle 8 months ago
1.94 in the works
👍️0
knrorrel knrorrel 8 months ago
great
👍️0
TheFinalCD TheFinalCD 8 months ago
https://dilutiontracker.com/app/search/BCDA
👍️0
TheFinalCD TheFinalCD 8 months ago
$BCDA NEWS https://finviz.com/quote.ashx?t=BCDA&p=d

https://dilutiontracker.com/app/search/BCDA
👍️0
subslover subslover 8 months ago
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in Q4 2024. In an interim analysis of available data to date for study patients followed up through two years, those having N-terminal pro B-type natriuretic peptide (NT-proBNP) levels consistent as demarcating heart failure (>500 pg/ml) at screening-baseline showed meaningful clinical improvements over controls, including a 59% relative risk reduction in heart death and a 54% relative risk reduction of Major Adverse Cardiovascular or Cerebrovascular events (MACCE). Further, all clinical outcome measures evaluated at follow-up for this interim subset favored cell therapy over guideline directed medical therapy, including having improved quality-of-life as measured using the Minnesota Living with Heart Failure Questionnaire, reduced NT-proBNP levels, greater walk distance as measured using the 6-minute walk distance test, and improved cardiac measures such as left ventricular ejection fraction and left ventricular end systolic and end diastolic volumes. Statistical significance (p
👍️0
Awl416 Awl416 8 months ago
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
👍️0
Biggiee Biggiee 9 months ago
Let’s do this
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
stock1ace1 stock1ace1 10 months ago
Bad news out .62 watch for the dump today
👍️0
Monksdream Monksdream 10 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 11 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 11 months ago
BCDA new 52 week low
👍️0
Monksdream Monksdream 11 months ago
BCDA new 52 week low
👍️0
willlbone willlbone 12 months ago
Shady day in Sunnyvale.
👍️0
PStockPickz PStockPickz 2 years ago
Nice open
👍️0
PStockPickz PStockPickz 2 years ago
Grabbed some $2.86
👍️0
PStockPickz PStockPickz 2 years ago
Time for another leg up!
👍️0
PStockPickz PStockPickz 2 years ago
https://finance.yahoo.com/news/biocardia-announces-fda-approval-ind-111500114.html
👍️0
PStockPickz PStockPickz 2 years ago
Looking good
👍️0
Awl416 Awl416 2 years ago
News
👍️0
Pro_Stock_Trader Pro_Stock_Trader 2 years ago
Going to be retesting highs here during power hour or after hours
👍️0
wesley_ wesley_ 3 years ago
$3.70 nice :)
👍️0
mplscubfan mplscubfan 3 years ago
Looking good here
👍️0
wesley_ wesley_ 3 years ago
$4.85 next leg up :)
👍️0
ClayTrader ClayTrader 4 years ago
* * $BCDA Video Chart 12-15-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ipo_dude ipo_dude 4 years ago
They anticipate .. not definitive
👍️0
Glider549 Glider549 4 years ago
Phase 3 DSMB feedback due December 17th
👍️0
ClayTrader ClayTrader 4 years ago
* * $BCDA Video Chart 12-14-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Pedro2004 Pedro2004 4 years ago
There we go. Finally broke $6.00 -- but the dump brought-it back to $5.75
👍️0
Pedro2004 Pedro2004 4 years ago
Someone keeps dumping blocks. But I'm keeping an eye on this the next few days.
👍️0
Pedro2004 Pedro2004 4 years ago
Some interesting trading this late afternoon. Low float.
👍️0

Your Recent History

NASDAQ
BCDA
BioCardia
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved